THIS ARTICLE IS AVAILABLE TO CPI SUBSCRIBERS
Please verify email or join us to access premium content!
In this issue: This issue looks at four health issues recently argued by the FTC. First we deal with the FDA’s REMS program and how it seems to conflict with the FTC’s desire to encourage generic competition. Then we present an indepth look, with three analyses, at the N.J. decision that Actavis applies only to cash settlements, […]
Please verify email or join us to access premium content!